ARTICLE

CURRENT PHARMACEUTICAL OPTIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

  1. HOME
  2. ARTICLE

01 Pages : 1-9

http://dx.doi.org/10.31703/gdddr.2019(IV-I).01      10.31703/gdddr.2019(IV-I).01      Published : Dec 2019

Current Pharmaceutical Options for the Treatment of Rheumatoid Arthritis

Abstract

    Rheumatoid arthritis is an inflammatory and autoimmune disease that describes the joints persistent inflammation and tendon sheets synovial lining. The primary symptoms of rheumatoid arthritis are stiffness, pain, and swelling of peripheral joints. Persistent inflammation results in many systemic and extra-articular manifestations involving many organ systems. Rheumatoid arthritis treatment goals are symptomatic management of pain, stiffness and restricted mobility. NSAIDs are commonly prescribed for people with rheumatoid arthritis. Analgesic effects of NSAIDs are based mainly on the inhibition of COX-enzyme and consequently the production of prostaglandins.

    Arthritis, Swelling, Inflammation, Treatment Options

    (1) Sobia Noreen
    Department of Pharmaceutics, Faculty of Pharmacy, The Islamia University of Bahawalpur, Punjab, Pakistan.
    (2) Hassan Mahmood
    Department of Humanities and Social Sciences, Khwaja Fareed University of Engineering and Information Technology (KFUEIT), Rahim yar Khan, Punjab, Pakistan.
    (3) Ifrah Hussain
    Department of Pharmacology, Faculty of Pharmacy, The Islamia University of Bahawalpur, Punjab, Pakistan.
Fulltext PDF

References

  • Bhatt, D. L., Scheiman, J., Abraham, N. S., Antman, E. M., Chan, F. K., Furberg, C. D., . . . Harrington, R. A. (2008). ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Journal of the American College of Cardiology, 52(18), 1502- 1517.
  • Choy, E. (2012). Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology, 51(suppl_5), v3-v11. doi: 10.1093/rheumatology/kes113
  • Clements, J. N. (2011). Tretment of rheumatoid arthritis: A review of recommendation and emergening therapy Formulary journal locum tenens, 1-7.
  • Cooles, F. A., & Isaacs, J. D. (2011). Pathophysiology of rheumatoid arthritis. Current opinion in rheumatology, 23(3), 233-240.
  • Cooles, F. A., & Isaacs, J. D. (2011). Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol, 23(3), 233-240. doi: 10.1097/BOR.0b013e32834518a3
  • Daniels, S., Robbins, J., West, C. R., & Nemeth, M. A. (2009). Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies. Clin Ther, 31(6), 1192-1208. doi: 10.1016/j.clinthera.2009.06.003
  • Dong, Q. L., Geoffrey, T., Jun, T., & Dong, W. (2008). The development of novel therapies for rheumatoid arthritis. eExpert opinion on therapeutic patents, 18(7), 723-738.
  • Fidahic, M., Jelicic Kadic, A., Radic, M., & Puljak, L. (2017). Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev, 6, Cd012095. doi: 10.1002/14651858.CD012095.pub2
  • Friedewald, V. E., Bennett, J. S., Christo, J. P., Pool, J. L., Scheiman, J. M., Simon, L. S., . . . Roberts, W. C. (2010). AJC Editor's consensus: Selective and nonselective nonsteroidal anti- inflammatory drugs and cardiovascular risk. The American journal of cardiology, 106(6), 873-884.
  • Futagami, S., Suzuki, K., Hiratsuka, T., Shindo, T., Hamamoto, T., Ueki, N., . . . Sakamoto, C. (2007). Chemopreventive effect of celecoxib in gastric cancer. Inflammopharmacology, 15(1), 1- 4. doi: 10.1007/s10787-006-1541-5
  • Hu, P. J., Yu, J., Zeng, Z. R., Leung, W. K., Lin, H. L., Tang, B. D., . . . Sung, J. J. Y. (2004). Chemoprevention of gastric cancer by celecoxib in rats. Gut, 53(2), 195-200. doi: 10.1136/gut.2003.021477
  • Kahlenberg, J. M., & Fox, D. A. (2011). Advances in the Medical Treatment of Rheumatoid Arthritis. Hand clinics, 27(1), 11-20. doi: 10.1016/j.hcl.2010.09.002
  • Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006). Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Bmj, 332(7553), 1302-1308.
  • Kısmet, K., Akay, M. T., Abbasoǧlu, O., & Ercan, A. (2004). Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detection and Prevention, 28(2), 127-142. doi: https://doi.org/10.1016/j.cdp.2003.12.005
  • Klarenbeek, N. B., Kerstens, P. J. S. M., Huizinga, T. W. J., Dijkmans, B. A. C., & Allaart, C. F. (2010). Recent advances in the management of rheumatoid arthritis. BMJ (Clinical research ed.), 341, c6942. http://europepmc.org/abstract/MED/21177351 https://doi.org/10.1136/bmj.c6942 doi:10.1136/bmj.c6942
  • Ma, M. H., Kingsley, G. H., & Scott, D. L. (2010). A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford), 49(1), 91-98. doi: 10.1093/rheumatology/kep331
  • Maqbool, I., Akhtar, M., Ahmad, R., Sadaquat, H., Noreen, S., Batool, A., & Khan, S. U. (2020). Novel multiparticulate pH triggered delayed release chronotherapeutic drug delivery of celecoxib-β-cyclodextrin inclusion complexes by using Box-Behnken design. European journal of pharmaceutical sciences, 146, 105254.
  • McInnes , I. B., & Schett , G. (2011). The Pathogenesis of Rheumatoid Arthritis. New England Journal of Medicine, 365(23), 2205- 2219. doi: 10.1056/NEJMra1004965
  • O'dell, J. R. (2004). Therapeutic strategies for rheumatoid arthritis. New England Journal of Medicine, 350(25), 2591-2602.
  • Silman, A. J., & Pearson, J. E. (2002). Epidemiology and genetics of rheumatoid arthritis. Arthritis Research, 4(Suppl 3), S265-S272. doi: 10.1186/ar578
  • Smolen, J. S., & Steiner, G. (2003). Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov, 2(6), 473-488. doi: http://www.nature.com/nrd/journal/v2/n6/sup pinfo/nrd1109_S1.html
  • Steiner, G., & Smolen, J. (2002). Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Research, 4(Suppl 2), S1- S5. doi: 10.1186/ar551
  • van Laar, M., Pergolizzi Jr, J. V., Mellinghoff, H.-U., Merchante, I. M., Nalamachu, S., O'Brien, J., . . . Raffa, R. B. (2012). Pain treatment in arthritis- related pain: beyond NSAIDs. The open rheumatology journal, 6, 320.
  • Verstappen, S. M. M., Jacobs, J. W. G., Bijlsma, J. W. J., Heurkens, A. H. M., van Booma-Frankfort, C., Borg, E. J. t., . . . van der Veen, M. J. (2003). Five-year followup of rheumatoid arthritis patients after early treatment with disease- modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis & Rheumatism, 48(7), 1797-1807. doi: 10.1002/art.11170
  • Walker, C., Essex, M. N., Li, C., & Park, P. W. (2016). Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients. Journal of International Medical Research, 44(3), 483- 495. doi: 10.1177/0300060516628704
  • Xu, C., Gu, K., Yasen, Y., & Hou, Y. (2016). Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. Medicine, 95(20), e3585. doi: 10.1097/md.0000000000003585
  • Zwerina, J., Redlich, K., Schett, G., & Smolen, J. S. (2005). Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci, 1051, 716-729. doi: 10.1196/annals.1361.116

Cite this article

APA

    APA : Noreen, S., Mahmood, H., & Hussain, I. (2019). Current Pharmaceutical Options for the Treatment of Rheumatoid Arthritis. Global Drug Design & Development Review, IV(I), 1-9. https://doi.org/10.31703/gdddr.2019(IV-I).01

CHICAGO

    CHICAGO : Noreen, Sobia, Hassan Mahmood, and Ifrah Hussain. 2019. "Current Pharmaceutical Options for the Treatment of Rheumatoid Arthritis." Global Drug Design & Development Review, IV (I): 1-9 doi: 10.31703/gdddr.2019(IV-I).01

HARVARD

    HARVARD : NOREEN, S., MAHMOOD, H. & HUSSAIN, I. 2019. Current Pharmaceutical Options for the Treatment of Rheumatoid Arthritis. Global Drug Design & Development Review, IV, 1-9.

MHRA

    MHRA : Noreen, Sobia, Hassan Mahmood, and Ifrah Hussain. 2019. "Current Pharmaceutical Options for the Treatment of Rheumatoid Arthritis." Global Drug Design & Development Review, IV: 1-9

MLA

    MLA : Noreen, Sobia, Hassan Mahmood, and Ifrah Hussain. "Current Pharmaceutical Options for the Treatment of Rheumatoid Arthritis." Global Drug Design & Development Review, IV.I (2019): 1-9 Print.

OXFORD

    OXFORD : Noreen, Sobia, Mahmood, Hassan, and Hussain, Ifrah (2019), "Current Pharmaceutical Options for the Treatment of Rheumatoid Arthritis", Global Drug Design & Development Review, IV (I), 1-9

TURABIAN

    TURABIAN : Noreen, Sobia, Hassan Mahmood, and Ifrah Hussain. "Current Pharmaceutical Options for the Treatment of Rheumatoid Arthritis." Global Drug Design & Development Review IV, no. I (2019): 1-9. https://doi.org/10.31703/gdddr.2019(IV-I).01